Primary Mediastinal B-Cell Lymphoma (PMBCL)Symptoms, Doctors, Treatments, Advances & More
Learn About Primary Mediastinal B-Cell Lymphoma (PMBCL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Maurizio Martelli practices practicing medicine in Rome, Italy. Mr. Martelli is rated as an Elite expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Tissue Biopsy, and Bone Marrow Transplant.
MedStar Georgetown University Hospital
Kieron Dunleavy is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Dunleavy is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration.
Cardiology Consultants
Mitchell Cairo is a Pediatrics provider practicing medicine in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Burkitt Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.
Summary: This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first. Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-...
Summary: This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: \- Pembrolizumab Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisoc...